ID Week

A study of more than 500 outpatient clinics reveals a new view of antibiotic overprescribing practices in the United States.

We sat down with several infectious disease experts to learn more about their research and asked them to share what they’re taking home from ID Week 2018.

Approximately 10% of US patients report having an allergic relation to penicillin, yet only 1% of the population are truly allergic.

Cristen Whittaker, PharmD, explains the findings of an analysis that compared length of stay, readmission, and costs in patients with ABSSSIs who received oritavancin or vancomycin.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.

Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.

Taking a closer look at the infectious disease risks posed by transplantation and what the future might have in store as the scope of transplantation expands.

Keith Kaye, MD, presented the analysis of the RESTORE-IMI 1 phase 3 trial which evaluated imipenem/cilastatin/relebactam versus imipenem/cilastatin plus colistin.

Kenneth E. Sherman, MD discusses the zoonotic hepatitis E virus and about the first reported case of rat-to-human transmission.

Melvin Weinstein, MD, discusses the current and emerging technologies for the laboratory diagnosis of bloodstream infections.

Roy Chemaly, MD, MPH discusses the findings of the phase 2 trial evaluating DAS181 for the treatment of parainfluenza virus lower respiratory tract infections in immunocompromised patients.

The stage may finally be set for the phage therapy era for recalcitrant bacterial infections.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, shares takeaways from her presentation on combination therapy for gram-negative agents at the 2018 SIDP Annual Meeting.

Efforts such as improved indication documentation and antimicrobial stewardship involvement may improve patient outcomes in some patients who are on outpatient parenteral antimicrobial therapy (OPAT) for ease of administration (EOA) that are readmitted to the hospital.

New software to facilitate prior authorization helped streamline the approval process and increase antimicrobial use tracking at the Hospital of the University of Pennsylvania.

Kenneth Sherman, MD, discusses current trends in the treatment of hepatitis B in immunocompromised patients and highlights research exploring treatment options for patients coinfected with HIV.

Letermovir found to prevent clinically significant CMV infection in HCT patients with CMV DNA when compared to placebo in recent phase 3 trial.

A retrospective study evaluates ceftolozane/tazobactam in a large database of US hospitals to determine real-world patterns and outcomes associated with the treatment.

The combination of daptomycin plus fosfomycin was more effective than daptomycin alone for treating patients with MRSA bacteremia.

Results indicate patients who received single-dose oritavancin were significantly less likely to be hospitalized, compared to those who received multidose vancomycin.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Instead, increasing duration of postoperative antimicrobial prophylaxis is associated with higher odds of acute kidney injury and C diff infection in a dose-dependent manner.

Study results indicate that clinicians start prescribing new drugs off-label almost as soon as the drugs become available.

First large-scale study on trends in invasive candidiasis finds species distribution of isolates varied between blood and nonblood sterile sites.

Delafloxacin was found to be relatively safe and well tolerated in patients with acute bacterial skin and skin structure infections with past or present cardiac or vascular difficulties.

A new analysis details the substantial burden of candidemia in the United States and calls for ongoing surveillance efforts to help assess the impact of prevention interventions.

Over one-third of patients with invasive aspergillosis lacked a documented immunosuppressive condition.

George Thompson, MD, principal investigator of the STRIVE study discusses optimal dosing for rezafungin in treating candidemia and/or invasive candidiasis.

Researcher give insight into the importance of antibiograms in outpatient management of urinary tract infections

New research finds patients with carbapenem-resistant bloodstream infections have a lower likelihood of surviving hospitalization or being discharged home.